Summary
Boston Scientific Corporation (BSX) has announced the closing of its acquisition of Vessix Vascular, Inc., a company specializing in a catheter-based renal denervation system for treating uncontrolled hypertension. This strategic move signals Boston Scientific's intent to expand its portfolio in the cardiovascular space and tap into the growing market for hypertension management solutions. The acquisition, previously announced on November 8, 2012, was officially completed on November 18, 2012, underscoring the company's commitment to advancing innovative medical technologies. Investors should view this acquisition as a potential growth driver for Boston Scientific. The renal denervation market, while emerging, holds significant promise for patients with resistant hypertension who have limited treatment options. By integrating Vessix Vascular's technology, Boston Scientific aims to strengthen its position in interventional cardiology and offer a more comprehensive suite of solutions to healthcare providers. The press release detailing the signing of the acquisition agreement is available as an exhibit to this filing.
Key Highlights
- 1Boston Scientific Corporation (BSX) has completed the acquisition of Vessix Vascular, Inc.
- 2Vessix Vascular is a developer of a catheter-based renal denervation system.
- 3The acquired technology targets the treatment of uncontrolled hypertension.
- 4This acquisition is a strategic move to expand BSX's cardiovascular product offerings.
- 5The acquisition was officially closed on November 18, 2012.
- 6The signing of the acquisition agreement was initially announced on November 8, 2012.